Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease

Posted Oct 02 2009 10:01pm


The Gammaglobulin Alzheimer’s Partnership Study (GAP)has added six new sites to its clinical trial.
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer´s Disease (AD).

Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
To read the inclusion/exclusion criteria and more about this Phase 3 clinical trial go here.

The study is being sponsored by National Institute on Aging (NIA), Alzheimer's Disease Cooperative Study (ADCS), and Baxter BioScience (Baxter Healthcare Corporation).

The six new sites are listed below.
Subscribe to The Alzheimer's Reading Room--via Email

Alabama: University of Alabama at Birmingham
Contact: Denise Ledlow, RN
205-934-6223
pdledlow@uab.edu

California: University of Southern California, Los Angeles
Contact: Mauricio Becerra
323-442-7534
mjbecerr@usc.edu

Florida: Roskamp Institute Memory Clinic,Sarasota
Contact: Cheryl Rindfleisch, RN, MHA
941-256-8018 ext.356
crindfleisch@rfdn.org

Nevada: Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas
Contact: Lal Ramani, MD
702-483-6025
ramanil@ccf.org

Rhode Island: Rhode Island Hospital, Providence
Contact: Teresa Erbozkurt, MA
401-444-6922
terbozkurt@Lifespan.org

Wisconsin: University of Wisconsin, Madison
Contact: Christine Khosropour, BS
608-256-1901 ext.11514
ck5@medicine.wisc.edu
Popular articles on the Alzheimer's Reading Room

The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Dementia, and Memory Loss

Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. The Alzheimer's Reading Room is the number one website on the Internet for news, advice, and insight into Alzheimer's disease. Bob has written more than 800 articles with more than 18,000 links on the Internet. Bob resides in Delray Beach, FL.

Original content Bob DeMarco, Alzheimer's Reading Room
Post a comment
Write a comment:

Related Searches